INKON Life Technology Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Wen Peng

Chief Executive Officer (CEO)

CN¥1.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.9yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Apr 23

What You Can Learn From INKON Life Technology Co., Ltd.'s (SZSE:300143) P/S

Mar 28

CEO

Wen Peng (55 yo)

2.8yrs

Permanencia

CN¥1,941,000

Compensación

Mr. Wen Peng has been General Manager of INKON Life Technology Co., Ltd. since August 25, 2021 and Non-Independent Director at since September 14, 2020. Mr. Peng served as the Deputy General Manager of INK...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Wen Peng	GM & Director	2.8yrs	CN¥1.94m	sin datos
Bo Tan	Financial Director	3.1yrs	CN¥644.00k	sin datos
Hongbo Li	Deputy General Manager	4.1yrs	CN¥556.00k	sin datos
Zelin Liu	Board Secretary	1.5yrs	CN¥26.00k	sin datos

2.9yrs

Permanencia media

46.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300143 se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Wen Peng	GM & Director	3.7yrs	CN¥1.94m	sin datos
Xiaolun Liu	Independent Director	5yrs	CN¥120.00k	sin datos
Lixia Tan	Chairman	5yrs	sin datos	sin datos
Xudong Shen	Non-Independent Director	5yrs	CN¥851.00k	sin datos
Jun Lu	Independent Director	5yrs	CN¥120.00k	sin datos
Gongyuan Tang	Independent Director	5yrs	CN¥120.00k	sin datos
Mianshun Pan	Non-Independent Director	3.7yrs	CN¥415.00k	sin datos
Wenwen Gong	Chairman of the Supervisory Board	3.7yrs	sin datos	sin datos
Ao Li	Employee Representative Supervisor	2.1yrs	sin datos	sin datos
Xiaoman Chen	Independent Director	less than a year	sin datos	sin datos
Yuan Du	Independent Director	less than a year	sin datos	sin datos
Feng Jiang	Independent Director	less than a year	sin datos	sin datos

3.7yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 300143 se considera experimentada (3.6 años de antigüedad promedio).

INKON Life Technology Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

High number of new directors

High number of new directors

High number of new and inexperienced directors

Recent updates

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

INKON Life Technology Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

What You Can Learn From INKON Life Technology Co., Ltd.'s (SZSE:300143) P/S

Price target decreased by 7.9% to CN¥12.27

INKON Life Technology Co., Ltd. (SZSE:300143) announces an Equity Buyback for CNY 80 million worth of its shares.

INKON Life Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.013 in 3Q 2022)

Now 21% undervalued after recent price drop

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

INKON Life Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.036 in 2Q 2022)

Full year 2022 earnings released: CN¥1.01 loss per share (vs CN¥0.57 loss in FY 2021)

Price target decreased to CN¥14.25

High number of new directors

High number of new directors

Qingdao Haiyingkang Investment Co., Ltd. and INKON Life Technology Co., Ltd. (SZSE:300143) agreed to acquire Shenzhen Shengzhong Investment Enterprise (Limited Partnership) from a group of shareholders for CNY 87.7 million.

Third quarter 2022 earnings released: EPS: CN¥0.013 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.036 (vs CN¥0.019 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥22.88

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.026 in 3Q 2020)

Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) for CNY 1.3 million.

Price target decreased to CN¥21.84

Second quarter 2021 earnings released: EPS CN¥0.019 (vs CN¥0.071 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.018 (vs CN¥0.021 loss in 1Q 2020)

INKON Life Technology Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥18.00

New 90-day low: CN¥20.30

New 90-day low: CN¥21.84

New 90-day low: CN¥22.19

Third quarter earnings released

First half earnings released

New 90-day high - CN¥25.53

INKON Life Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

INKON Life Technology Co., Ltd. announced that it has received CNY 732.939997 million in funding from Qingdao Yingkang Medical Investment Co., Ltd.

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad